

FluCov Influenza Activity Report #11

5 February 2024


Take home: continued elevated influenza activity in the Northern Hemisphere

- North America and Europe:** Influenza activity is increasing with moderate to high activity in many U.S states. In Europe, influenza activity is also increasing in most countries (Denmark, France, Germany, The Netherlands, UK) with moderate to high activity. In Italy and Spain, influenza activity is decreasing but activity remains around 20%.
- Asia:** Influenza overall positivity rate decreased in China, but remained around 30% in week 04/2024, moderate activity is now reported in Northern China and medium activity is reported in Southern China.
- Circulating virus:** While A/H3 and B/Victoria have predominated globally and in China, A/H1N1pdm09 has dominated circulation in most of the Northern Hemisphere. Presently, there are no documented cases of B-Yamagata
- Vaccine match:** Early indicators in the US suggest good vaccine match. France reports good match with A/H1N1pdm09, but mismatch in some percentage of A/H3 viruses. The mismatch viruses seem to be in the same genetic clade as the strain recommended for 2024 SH vaccine.
- Influenza Viruses of Pandemic Potential:** Monitoring of a fatal H10N5/H3N2 coinfecting case, in a 63-year-old female with underlying medical problems reported from China in December, showed no human-to-human transmission (Promed).
- COVID hospitalizations:** Are decreasing in Italy and the US, after a peak around the end of 2023. For England, the last update was on 7 December 2023, hospitalizations were increasing at the time, after a period of decrease.

Positive Influenza tests (%)


Note: Denmark, France, Germany, Italy and UK positivity rate graph was last updated week 03/2024.

— Season 2023/2024
 — Season 2022/2023
 — Season 2021/2022
 — Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



Weekly hospital SARS-CoV-2 hospital admissions

(US, Italy, England; admissions/million)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Most recent estimates subject to change (e.g. may decline) due to ongoing testing of specimen. Data only available for three countries at the moment.

Data sources & details

China: China CDC
US: FluView (Clinical Laboratories)
NL & Spain: ERVISS
DK: WHO FluNET (non-sentinel)
All others: WHO FluNet (sentinel)
COVID: Our World in Data.

A Nivel publication

FluCov team: Susanne Heemskerk, Bronke Boudewijns, Marco Del Riccio, Saverio Caini, John Paget.

FluCov Influenza Activity Report #11: 5 February 2024. Netherlands, Utrecht: Nivel, 2024

Websites for more information

Project Website: <https://www.nivel.nl/en/flucoV>

FluCoV Dashboard: <https://www.nivel.nl/en/flucoV-dashboard>

Funding

The Nivel FluCov project is funded by Sanofi
